Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01531205 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01531205 is a Phase 2 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 2 participants.
The verdict
NCT01531205, a Phase 2 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The aim of this study is to test whether adding chemotherapy/cabazitaxel and hormonal/androgen deprivation therapy before surgical removal of your prostate would improve the outcome of salvage surgery for locally recurrent prostate cancer after the initial primary radiation therapy.
Interventions
- DRUG Cabazitaxel
- DRUG Androgen Ablation
- DRUG Salvage Therapy
- DRUG Neoadjuvant Treatment - Hormonal Therapy
- DRUG Neoadjuvant Treatment - Cabazitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01531205
The ClinicalTrials.gov registry entry for NCT01531205 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cabazitaxel is the first listed.
NCT01531205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01531205 about?
NCT01531205 is a clinical study titled "Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA". The aim of this study is to test whether adding chemotherapy/cabazitaxel and hormonal/androgen deprivation therapy before surgical removal of your prostate would improve the outcome of salvage surgery for locally recurrent prostate cancer after the initial primary radiation therapy.
What is the current status of trial NCT01531205?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2012-05. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01531205?
The interventions under investigation include: Cabazitaxel (DRUG), Androgen Ablation (DRUG), Salvage Therapy (DRUG), Neoadjuvant Treatment - Hormonal Therapy (DRUG), Neoadjuvant Treatment - Cabazitaxel (DRUG).
Who is sponsoring clinical trial NCT01531205?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.